Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CERB-219-25 | Other Identifier | Biomedical Research Ethics Committee (CERB), Mohammed V University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ibn Sina University Hospital, Rabat, Morocco | OTHER |
Not provided
Not provided
Not provided
Not provided
The purpose of this clinical trial is to evaluate whether using pharmacogenetic testing to guide antidepressant treatment can improve outcomes in adults with major depressive disorder in Morocco. Depression is a common mental health condition, and finding the most effective antidepressant for a patient can take time. Some individuals do not respond well to the first medication prescribed or may experience side effects.
Pharmacogenetic testing examines genetic variations that can influence how a person processes certain medications. Information about genes involved in drug metabolism, such as CYP2D6 and CYP2C19, may help clinicians choose antidepressants and adjust doses more appropriately for each patient.
The main question this study aims to answer is whether treatment guided by pharmacogenetic test results leads to higher remission rates of depressive symptoms compared with usual clinical care.
In this study, participants diagnosed with major depressive disorder will be randomly assigned to one of two groups. In the pharmacogenetic-guided group, clinicians will receive the patient's genetic test results and may use this information to guide antidepressant selection and dosing. In the usual care group, antidepressant treatment will be prescribed according to standard clinical practice without access to pharmacogenetic information.
Participants will receive antidepressant treatment and will be followed for 12 weeks. During this period, depressive symptoms will be evaluated using standardized clinical questionnaires, including the Patient Health Questionnaire (PHQ-9). Information on treatment response, medication tolerance, and adverse effects will also be collected.
This study aims to provide evidence on the potential role of pharmacogenetic-guided treatment in improving depression management and to support the development of personalized medicine approaches in psychiatric care in Morocco.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pharmacogenetic-Guided Treatment | Experimental |
| |
| Usual Care | Active Comparator | Participants receive standard antidepressant treatment according to routine clinical practice without access to pharmacogenetic test results. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pharmacogenetic-Guided Treatment | Diagnostic Test | Pharmacogenetic testing used to support personalized antidepressant treatment selection and dose adjustment according to the validated laboratory platform and applicable pharmacogenetic recommendations. |
| Measure | Description | Time Frame |
|---|---|---|
| Depression Severity | Severity of depressive symptoms assessed using the 17-item Hamilton Depression Rating Scale (HAM-D17), a clinician-rated scale ranging from 0 to 52, where higher scores indicate greater depression severity and worse outcomes. The outcome will be analyzed as the change in HAM-D17 total score from baseline to 12 weeks post-randomization. A greater decrease in score reflects greater clinical improvement. | 12 weeks post-randomization |
| Measure | Description | Time Frame |
|---|---|---|
| Depression Remission | Depression remission at 12 weeks post-randomization, assessed using the 17-item Hamilton Depression Rating Scale (HAM-D17), a clinician-rated scale ranging from 0 to 52, where higher scores indicate greater depression severity and worse outcomes. Remission is defined as a HAM-D17 total score of 7 or less. The outcome will be analyzed as the proportion of participants meeting remission criteria at week 12. |
| Measure | Description | Time Frame |
|---|---|---|
| Sustained Depression Remission | Sustained remission of depressive symptoms from 12 to 24 weeks post-randomization, assessed using the 17-item Hamilton Depression Rating Scale (HAM-D17), a clinician-rated scale ranging from 0 to 52, where higher scores indicate greater depression severity and worse outcomes. Sustained remission is defined as meeting remission criteria, defined as a HAM-D17 total score of 7 or less, at 12 weeks and remaining in remission at 24 weeks. The outcome will be analyzed as the proportion of participants maintaining remission across both time points. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Meriem Atarki, PhD | Contact | +212687595174 | meriem_atarki@um5.ac.ma |
| Name | Affiliation | Role |
|---|---|---|
| Meriem Atarki, PhD | Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ar-Razi Psychiatric Hospital, Ibn Sina University Hospital | Rabat | Rabat-Salé-Kénitra | 40000 | Morocco |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D003863 | Depression |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D001526 | Behavioral Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Usual Care | Other | Participants in the control group will receive standard antidepressant treatment according to routine clinical practice. Treatment decisions, including antidepressant selection and dose adjustments, will be made by the treating clinician without access to pharmacogenetic test results |
|
|
| 12 weeks post-randomization |
| Depression Response | Treatment response at 12 weeks post-randomization, assessed using the 17-item Hamilton Depression Rating Scale (HAM-D17), a clinician-rated scale ranging from 0 to 52, where higher scores indicate greater depression severity and worse outcomes. Response is defined as a reduction of 50 percent or more in HAM-D17 total score from baseline to week 12. The outcome will be analyzed as the proportion of participants meeting response criteria. | 12 weeks post-randomization |
| Medication Tolerability | Tolerability of antidepressant treatment assessed using the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale. The FIBSER evaluates three domains (frequency, intensity, and burden of side effects), each scored from 0 to 6, yielding a total score ranging from 0 to 18, where higher total scores indicate greater side effect burden and worse tolerability outcomes. | 12 weeks post-randomization |
| Global Clinical Improvement | Global clinical improvement assessed using the Clinical Global Impression-Improvement (CGI-I) scale, a clinician-rated instrument scored from 1 to 7, where 1 indicates very much improved and 7 indicates very much worse. Lower scores reflect better clinical outcomes. | 12 weeks post-randomization |
| 24 weeks post-randomization |
| D001519 |
| Behavior |